Do you want to read an article? Please log in or register.
Thromboembolic Risk in Ulcerative Colitis Patients on Advanced Therapy: A Real-World Data Analysis
Inflammatory Bowel Disease
Related content
Inflammatory Bowel Disease
Impact of Type 2 Diabetes on Clinical Outcomes and Advanced Therapy Use in Patients with Crohn's Disease: a Real-World Propensity Score-Matched Analysis
J Crohns Colitis
Massironi S, Solitano V, Furfaro F, D'Amico F, Zilli A, Allocca M, Peyrin-Biroulet L, Jairath V, Danese S
doi: 10.1093/ecco-jcc/jjaf157
RECOMMENDED
Inflammatory Bowel Disease
Efficacy of 5-Aminosalicylic Acid Continuation versus Discontinuation in Patients with Ulcerative Colitis Escalated to Advanced Therapy: A Systematic Review and Meta-Analysis of Adjusted Effect Estimates
★ 1
Recommended by
Prof. Dr Stephan Vavricka, Faculty Member
J Crohns Colitis
Sul HH, Gewehr DM, Kang H, Junior OR, Ungaro RC, Bernstein CN
doi: 10.1093/ecco-jcc/jjaf202
Inflammatory Bowel Disease
Real-World Outcomes of Glucagon-Like Peptide-1 Receptor Agonist Therapy in Obese Patients With Ulcerative Colitis and IPAA With a History of Pouchitis
Inflamm Bowel Dis
Desai A, Habib H, Khataniar H, Farraye FA, Sehgal P, Barnes EL, Kochhar GS, Hashash JG
doi: 10.1093/ibd/izaf301
RECOMMENDED
Further Publications
Real-world effectiveness of advanced therapies in microscopic colitis
★ 2
Recommended by
Prof. Dr Stephan Vavricka, Faculty Member
Clin Gastroenterol Hepatol
Verstockt B, Taelman T, Din S, Vavricka SR, Blesl A, Zabana Y, Van Moerkercke W, Kiudelis V, de la Revilla Negro J, Maillard MH, Savarino EV, Teich N, Macaigne G, Truyens M, Ribaldone DG, Barreiro-de Acosta M, Wildt S, Rivière P, Fumery M, Amiot A, Marsal J, Tontini GE, Levartovsky A, Vieujean S, Somers M, Cremer A, Lutakov I, Cohen NA, Dewit S, Bajer L, Rahier JF, Backman AS, Nancey S, Choden T, Van Dongen J, Rogler G, Lenfant M, Finlayson M, Münch A, Julsgaard M
doi: 10.1016/j.cgh.2025.12.019
Inflammatory Bowel Disease
Placebo rates in randomised clinical trials of ulcerative colitis: An individual patient data meta-analysis
J Crohns Colitis
Solitano V, Hogan M, Singh S, Danese S, Peyrin-Biroulet L, Vuyyuru S, Macdonald JK, Zou G, Yuan Y, Sands BE, Panaccione R, Feagan BG, Hanzel J, Sedano R, Dulai P, Narula N, Ma C, Jairath V
doi: 10.1093/ecco-jcc/jjaf191
Inflammatory Bowel Disease
Real-world comparison of the effectiveness of tofacitinib and ustekinumab in patients with ulcerative colitis: the TORUS study
Clin Gastroenterol Hepatol
Buisson A, Serrero M, Altwegg R, Guilmoteau T, Bouguen G, Nachury M, Amiot A, Vuitton L, Treton X, Caillo L, Pereira B, Fumery M
doi: 10.1016/j.cgh.2025.07.044
Inflammatory Bowel Disease
Treatment sequences, outcomes, healthcare utilization, and costs in patients with inflammatory bowel diseases requiring advanced treatment-real world comparative effectiveness from German claims data
BMC Gastroenterol
Dignass A, Teich N, Kaiser S, Sünwoldt J, Dünweber C, Weinhold I, Borchert J, Kudernatsch R
doi: 10.1186/s12876-025-04022-7
Inflammatory Bowel Disease
Clinical Response for 12 Months or More to the First Advanced Therapy is Associated with a Significant Decrease in the Long-Term Risk of Hospitalization: A Nation-Wide Analysis of Patients From the UK Inflammatory Bowel Disease (IBD) BioResource
Inflamm Bowel Dis
Yan K, Vuyyuru SK, Taylor A, Figueredo G, Raine T, Sanon M, Naessens D, Munje C, Moran GW
doi: 10.1093/ibd/izaf276
Further Publications
Efficacy and safety of vedolizumab in elderly and younger patients with moderate-to-severe ulcerative colitis: a retrospective real-world study in China
BMC Gastroenterol
Zhang H, Ding XL, Xu YH, Wu J, Wang YY, Liu SX, Yan J, Liu H, Tian ZB, Liu AL
doi: 10.1186/s12876-025-04125-1